

Greg Yothers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6207467/publications.pdf>

Version: 2024-02-01

130
papers

19,136
citations

34105
52
h-index

19190
118
g-index

133
all docs

133
docs citations

133
times ranked

17058
citing authors

#	ARTICLE	IF	CITATIONS
1	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Journal of the National Cancer Institute, 2022, 114, 60-67.	6.3	5
2	NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).. Journal of Clinical Oncology, 2022, 40, TPS212-TPS212.	1.6	4
3	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2022, 40, TPS233-TPS233.	1.6	1
4	NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) studyâ€”A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, TPS232-TPS232.	1.6	3
5	Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.. Journal of Clinical Oncology, 2022, 40, 140-140.	1.6	0
6	Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.. Journal of Clinical Oncology, 2022, 40, 99-99.	1.6	8
7	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. Journal of Gastrointestinal Oncology, 2022, 13, 126-136.	1.4	1
8	Healthâ€”related quality of life outcomes after neoadjuvantâ€”chemoradiotherapy for rectal cancer in <sc>NRG</sc>â€”Oncology/<sc>NSABP</sc> Râ€”04. Cancer, 2022, 128, 3233-3242.	4.1	3
9	A Statistical Method for Association Analysis of Cell Type Compositions. Statistics in Biosciences, 2021, 13, 373-385.	1.2	0
10	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 404-411.	2.5	1
11	On the properties of the toxicity index and its statistical efficiency. Statistics in Medicine, 2021, 40, 1535-1552.	1.6	13
12	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34â€”640 Patients in the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 400-407.	6.3	44
13	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2021, 39, TPS148-TPS148.	1.6	2
14	NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)â€”Pembrolizumab experimental arm (EA) primary results.. Journal of Clinical Oncology, 2021, 39, 8-8.	1.6	17
15	NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-therapy (COMMIT) Studyâ€”A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, TPS150-TPS150.	1.6	2
16	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Journal of Clinical Oncology, 2021, 39, 642-651.	1.6	84
17	Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.. Journal of Clinical Oncology, 2021, 39, 3516-3516.	1.6	0
18	Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2021, 39, TPS3622-TPS3622.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.. Journal of Clinical Oncology, 2021, 39, 3597-3597.	1.6	0
20	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)â€”NRG-GI004/SWOG-S1610.. Journal of Clinical Oncology, 2021, 39, TPS3618-TPS3618.	1.6	6
21	Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.. Journal of Clinical Oncology, 2021, 39, 3599-3599.	1.6	0
22	OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline <i>BRCA1/2</i> mutations and high-risk HER2-negative early breast cancer.. Journal of Clinical Oncology, 2021, 39, LBA1-LBA1.	1.6	26
23	Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer. New England Journal of Medicine, 2021, 384, 2394-2405.	27.0	764
24	Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clinical Colorectal Cancer, 2021, 20, 130-136.	2.3	5
25	Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology, 2021, 7, 1225.	7.1	82
26	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 1693-1704.	6.3	25
27	Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. Journal of Clinical Oncology, 2021, 39, 3800-3812.	1.6	6
28	Visualizing adverse events in clinical trials using correspondence analysis with R-package visae. BMC Medical Research Methodology, 2021, 21, 244.	3.1	2
29	Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. Clinical Gastroenterology and Hepatology, 2020, 18, 2717-2723.e3.	4.4	7
30	Assessing the Quality of Rectal Cancer Pathology Reports in National Surgical Adjuvant Breast and Bowel Project Protocol R-04/NRG Oncology. Diseases of the Colon and Rectum, 2020, 63, 1063-1070.	1.3	4
31	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€”Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
32	Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Annals of Oncology, 2020, 31, 480-486.	1.2	23
33	Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index. Journal of the National Cancer Institute, 2020, 112, 1266-1274.	6.3	24
34	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. European Journal of Cancer, 2020, 130, 63-71.	2.8	15
35	Abstract OT2-02-03: NSABP FB-13: An assessment of the biological and clinical effects of palbociclib with ovarian suppression and letrozole in the neoadjuvant treatment of pts (pts) with premenopausal (preM) estrogen-receptor positive/HER2-negative primary breast cancer. , 2020, , .		2
36	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2020, 38, TPS4121-TPS4121.	1.6	3

#	ARTICLE	IF	CITATIONS
37	A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).. Journal of Clinical Oncology, 2020, 38, TPS260-TPS260.	1.6	4
38	NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.. Journal of Clinical Oncology, 2020, 38, TPS264-TPS264.	1.6	2
39	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. Journal of Clinical Oncology, 2020, 38, 4099-4099.	1.6	1
40	Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: Analysis of MOSAIC and C-07 trials.. Journal of Clinical Oncology, 2020, 38, 118-118.	1.6	0
41	NSABP FC-10: Phase IB study of pembrolizumab in combination with premetrexed + oaliplatin in patients (pts) with chemo-refractory metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2020, 38, TPS262-TPS262.	1.6	0
42	NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.. Journal of Clinical Oncology, 2020, 38, TPS261-TPS261.	1.6	12
43	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Annals of Oncology, 2019, 30, 1466-1471.	1.2	97
44	NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)â€™ First experimental arm (EA) initial results.. Journal of Clinical Oncology, 2019, 37, 3505-3505.	1.6	26
45	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.. Journal of Clinical Oncology, 2019, 37, 3525-3525.	1.6	1
46	Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2.. Journal of Clinical Oncology, 2019, 37, TPS3620-TPS3620.	1.6	1
47	Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapy. Annals of Oncology, 2019, 30, v52.	1.2	0
48	Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). British Journal of Cancer, 2018, 118, 629-633.	6.4	18
49	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clinical Cancer Research, 2018, 24, 3500-3509.	7.0	3
50	Genome-wide association with survival in stage II-III colon cancer clinical trials (NCCTG N0147,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22 2018, 36, 3582-3582.	1.6	2
51	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. JAMA Oncology, 2017, 3, 472.	7.1	82
52	Quality of life and symptoms in long-term survivors of colorectal cancer: results from NSABP protocol LTS-01. Journal of Cancer Survivorship, 2017, 11, 111-118.	2.9	30
53	Anthracyclines in Early Breast Cancer: The ABC Trialsâ€™USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). Journal of Clinical Oncology, 2017, 35, 2647-2655.	1.6	223
54	Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform.. Journal of Clinical Oncology, 2017, 35, TPS814-TPS814.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. <i>Journal of Geriatric Oncology</i> , 2016, 7, 422-429.	1.0	9
56	Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes. <i>JAMA Oncology</i> , 2016, 2, 1162.	7.1	140
57	CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 211-222.	27.0	388
58	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	1.6	32
59	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 843-853.	1.6	128
60	Cancer Hallmark-Based Gene Sets and Personalized Medicine for Patients With Stage II Colon Cancer. <i>JAMA Oncology</i> , 2016, 2, 23.	7.1	5
61	Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090,) Tj ETQq1 1 0.784314 rgBT /Overall survival in women with high-risk, HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1000-1000.	1.6	12
62	Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3510-3510.	1.6	1
63	Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3533-3533.	1.6	10
64	A phase II clinical trial platform utilizing total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3638-TPS3638.	1.6	3
65	Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3620-3620.	1.6	0
66	Comparative Effectiveness of Sphincter-Sparing Surgery Versus Abdominoperineal Resection in Rectal Cancer. <i>Annals of Surgery</i> , 2015, 261, 144-148.	4.2	50
67	Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 275-280.	0.5	115
68	Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. <i>Annals of Oncology</i> , 2015, 26, 950-958.	1.2	11
69	Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. <i>Annals of Oncology</i> , 2015, 26, 715-724.	1.2	104
70	Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv248.	6.3	242
71	Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 1481-1492.	10.7	139
72	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	62

#	ARTICLE	IF	CITATIONS
73	Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04. <i>Journal of Clinical Oncology</i> , 2014, 32, 1927-1934.	1.6	373
74	Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. <i>Projecting Analysis Dates for the IDEA Collaboration. Forum of Clinical Oncology</i> , 2014, 5, 1-7.	0.2	2
75	Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3507-3507.	1.6	53
76	Neoadjuvant rectal cancer (RC) score to predict survival: Potential surrogate endpoint for early phase trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3533-3533.	1.6	17
77	Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 359-364.	1.6	187
78	Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2013, 31, 4512-4519.	1.6	155
79	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. <i>Cancer</i> , 2013, 119, 1528-1536.	4.1	141
80	Colon Cancer Mutation: Prognosis/Predictionâ€“Response. <i>Clinical Cancer Research</i> , 2013, 19, 1301-1301.	7.0	24
81	The Predictive and Prognostic Value of Sex inâ€“Early-Stage Colon Cancer: A Pooled Analysis ofâ€“33,345 Patients from the ACCENT Database. <i>Clinical Colorectal Cancer</i> , 2013, 12, 179-187.	2.3	27
82	Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2600-2606.	1.6	211
83	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 3656-3663.	1.6	65
84	Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08. <i>Journal of the National Cancer Institute</i> , 2013, 105, 989-992.	6.3	56
85	Innovative estimation of survival using log-normal survival modelling on ACCENT database. <i>British Journal of Cancer</i> , 2013, 108, 784-790.	6.4	17
86	A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials. <i>Clinical Trials</i> , 2012, 9, 385-395.	1.6	27
87	Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3792-3799.	1.6	446
88	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. <i>Journal of Clinical Oncology</i> , 2012, 30, 2334-2339.	1.6	34
89	Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. <i>Clinical Cancer Research</i> , 2012, 18, 6531-6541.	7.0	272
90	Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 406-412.	1.6	51

#	ARTICLE	IF	CITATIONS
91	Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10. <i>Journal of Clinical Oncology</i> , 2012, 30, 3223-3228.	1.6	145
92	Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. <i>Cancer</i> , 2012, 118, 5614-5622.	4.1	76
93	DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 863-875.	6.3	469
94	Simultaneous confidence band for the difference of segmented linear models. <i>Journal of Statistical Planning and Inference</i> , 2011, 141, 1059-1068.	0.6	3
95	Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08. <i>Journal of Clinical Oncology</i> , 2011, 29, 11-16.	1.6	551
96	Multiagent Regimens for Metastatic Colorectal Cancer: If Some Is Good, More Must Be Better. <i>Journal of the National Cancer Institute</i> , 2011, 103, 4-5.	6.3	1
97	Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2011, 29, 3768-3774.	1.6	560
98	Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1498-1506.	6.3	61
99	Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival. <i>Clinical Trials</i> , 2011, 8, 581-590.	1.6	7
100	Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant Trials. <i>Annals of Surgical Oncology</i> , 2010, 17, 959-966.	1.5	117
101	National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. <i>Journal of the National Cancer Institute</i> , 2010, 102, 161-169.	6.3	224
102	Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin. <i>Journal of Clinical Oncology</i> , 2010, 28, 3937-3944.	1.6	271
103	Routine Preventive Care and Cancer Surveillance in Long-Term Survivors of Colorectal Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01. <i>Journal of Clinical Oncology</i> , 2010, 28, 5274-5279.	1.6	14
104	Conditional Survival and the Choice of Conditioning Set for Patients With Colon Cancer: An Analysis of NSABP Trials C-03 Through C-07. <i>Journal of Clinical Oncology</i> , 2010, 28, 2544-2548.	1.6	87
105	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. <i>Journal of Clinical Oncology</i> , 2010, 28, 460-465.	1.6	67
106	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 872-877.	1.6	539
107	Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03. <i>Journal of Clinical Oncology</i> , 2009, 27, 5124-5130.	1.6	796
108	Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3385-3390.	1.6	244

#	ARTICLE	IF	CITATIONS
109	Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. <i>Journal of Cancer Survivorship</i> , 2009, 3, 137-147.	2.9	44
110	NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). <i>NIH Consensus and State-of-the-science Statements</i> , 2009, 26, 1-27.	7.0	30
111	Exploring and validating surrogate endpoints in colorectal cancer. <i>Lifetime Data Analysis</i> , 2008, 14, 54-64.	0.9	30
112	FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer. <i>Cancer Investigation</i> , 2008, 26, 956-963.	1.3	58
113	Surrogate endpoint validation: statistical elegance versus clinical relevance. <i>Statistical Methods in Medical Research</i> , 2008, 17, 477-486.	1.5	26
114	Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07. <i>Journal of Clinical Oncology</i> , 2007, 25, 2198-2204.	1.6	955
115	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4569-4574.	1.6	220
116	Toward Progression-Free Survival As a Primary End Point in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5153-5154.	1.6	34
117	End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal. <i>Journal of Clinical Oncology</i> , 2007, 25, 3572-3575.	1.6	66
118	Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06. <i>Journal of Clinical Oncology</i> , 2007, 25, 424-430.	1.6	60
119	Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin. <i>Cancer</i> , 2007, 110, 1945-1950.	4.1	42
120	Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. <i>BMC Genomics</i> , 2007, 8, 279.	2.8	46
121	Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1647-1654.	6.3	317
122	Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06. <i>Journal of Clinical Oncology</i> , 2006, 24, 2059-2064.	1.6	297
123	Randomization in Phase II Clinical Trials. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 776-8.	0.3	3
124	Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28. <i>Journal of Clinical Oncology</i> , 2005, 23, 3686-3696.	1.6	585
125	Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31. <i>Journal of Clinical Oncology</i> , 2005, 23, 7811-7819.	1.6	722
126	Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1673-1684.	27.0	4,956

#	ARTICLE	IF	CITATIONS
127	Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23. <i>Breast Cancer Research and Treatment</i> , 2004, 86, 153-164.	2.5	61
128	Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience. <i>Journal of the National Cancer Institute</i> , 2002, 94, 852-854.	6.3	463
129	Multinational study of pneumococcal serotypes causing acute otitis media in children. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 1008-1016.	2.0	114
130	HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1991-1998.	6.3	258